Although it has been reported that prostate tumor-derived exosomes can enrich biomarker PSMA (28,29), by using both of LNCaP and CWR22Rv1 cells, our data further confirmed the enrichment of exosomal PSMA without regard to androgen-dependence or -independence of PSMA-positive prostate cancer cells. This evidence concerns the gene FOLH1 and prostate carcinoma.